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Stage&0& Tis& N0& M0&
Stage&IA& T1a,&b& N0& M0&
Stage&IB& T2a& N0& M0&
Stage&IIA& T2b& N0& M0&
& T1a,&b& N1& M0&
& T2a& N1& M0&
Stage&IIB& T2b& N1& M0&
& T3& N0& M0&
Stage&IIIA& T1a,&b,&T2a,&b& N2& M0&
& T3& N1,&N2& M0&
& T4& N0,&N1& M0&
Stage&IIIB& T4& N2& M0&
& Any&T& N3& M0&






















































































































































































































































































































































































































































































































































































































































































































































































































& & No..of.items. Question.no..




















































































































































































pn ⋅ 1− pn( ) + ps 1− ps( )
pn − ps( )
2 ⋅ c =






































Treatment.group. Chemo. CRT. Total.
PS.2. 19&(20.2)& 21&(22.3)& 40&(21.3)&
Tumor.≥.8.cm. 45&(47.9)& 56&(59.6)& 101&(53.7)&
Weight.loss.≥.10%.last.6.months. 31&(33.0)& 39&(41.5)& 70&(37.2)&









































. & & Radiation& & & & & & & &
CRF. 1+2& 3& 4& 5+6& 7& 8+9& 10& 11& 12& 13& 14&
Biochemistry. X& & X& X& X& X& X& X& X& X& X&
Chest.Xdray. X& & X& X& X& X& X& X& X& X& X&
CT.Thorax.+up.
abd.
X& & & & & X& In&field&relapse&





































































Adverse.Event. 1. 2. 3. 4. 5.
Hemoglobin. <LLN&–&10&g/dL& <&10.0&–&8.0&g/dL& <&8.0&–&6.5&g/dL& <&6.5&g/dL& Death&
Neutrophils/.
Granulocytes.
<LLN&–&1.5&x&109&/L& <&1.5&−&1.0&x&109&/L& <&1.0&–&0.5&x&109&/L& <&0.5&x&109&/L& Death&







































































































































































































































































































Stage. 1988d1992. 1993d1997. 1998d2002. 2003d2007.
. M. F. M. F. M. F. M. F.
Localized.disease...............(Stage.I). 40& 37& 38& 38& 29& 29& 25& 27&
Regional.disease...............(Stages.II.&.III). 19& 20& 22& 20& 25& 23& 29& 26&
Metastatic.disease..........(Stage.IV). 40& 42& 39& 40& 46& 48& 45& 46&

























































































































































































































































































B& SE& Wald& df& Sig.& Exp(B)& Lower& Upper&
Chemotherapy/CRT& e.600& .164& 13.461& 1& .000& .549& .398& .756&
Gender& .291& .169& 2.981& 1& .084& 1.338& .961& 1.861&
Performance&Status&&(0e1&versus&2)& .620& .197& 9.920& 1& .002& 1.858& 1.264& 2.733&
10%&Weight&loss&last&6&months& .141& .170& .685& 1& .408& 1.151& .825& 1.606&
Tumor&diameter& e.042& .031& 1.740& 1& .187& .959& .902& 1.020&
Age& e.007& .010& .465& 1& .495& .993& .974& 1.013&
In&order&not&to&loose&information,&age&and&tumor&diameter&were&not&dichotomized&in&this&analysis!
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& Doing&a&separate&multivariate&analysis&for&each&of&the&two&treatment&arms,&confirmed&
that&PS&was&not&a&negative&predictive&factor&in&the&chemotherapy&arm&(HR&1.68,&CI&0.95&e2.95,&
p=0.074).&However,&in&the&CRT&arm&it&was&highly&significant:&(HR&2.1,&CI&1.2&–&3.5,&p=0.007)..
The&distribution&of&negative&prognostic&factors&is&shown&in&Table&6.&Considering&the&
negative&impact&of&PS&2,&the&Conrad&study&would&not&have&been&as&illustrative,&had&the&study&
population&been&normally&distributed&regarding&PS&2,&i.e.&if&the&PS&2&group&had&constituted&
40%&of&the&whole&study&population.&&
&
8.6.Paper.2.d.The.Influence.of.Tumor.Size.
A&tumor&diameter&of&8&cm&or&larger&was&one&of&the&criteria&to&be&included&in&the&trial.&
Another&requirement&was&the&possibility&to&include&the&tumor&in&a&pragmatic&radiation&field.&
Accordingly,&our&material&consists&of&selected&patients&with&tumors&larger&than&normal,&
especially&fit&for&radiation.&.
We&found&a&significant&increased&survival&in&the&group&of&patients&with&tumors&>&7&cm&
compared&to&the&group&with&tumors&≤&7&cm.&It&is&important&to&state&that&the&Conrad&trial&was&
not&designed&to&study&this&issue.&The&significant&increased&survival&in&the&large&tumor&group&
compared&to&the&group&with&smaller&tumors&is&probably&a&bias&caused&by&the&selection&of&
tumors&fit&for&radiation.&&
Gender&and&weight&loss&were&not&significant&predictive&factors&in&our&study.&However,&
these&are&factors&known&to&influence&survival158e163.&In&our&study,&there&were&a&predominance&
of&women&in&the&tumor&>7&cm&group,&but&less&weight&loss,&especially&for&those&treated&with&
CRT.&This&may&have&contributed&to&the&increased&survival&in&the&group&of&tumors&>&7&cm.&
However,&poor&performance&status&(PS&2),&which&is&one&of&the&strongest&prognostic&factors&in&
NSCLC,&was&over&represented&in&the&tumor&>7&cm&group&and&especially&for&the&CRT&treated.&&
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Many&authors&have&found&the&TNM&classification&system&insufficient&in&predicting&the&
treatment&effect&on&survival&in&noneoperable&NSCLCepatients,&especially&with&respect&to&the&
impact&of&tumor&size164e166.&Some&have&even&tried&to&propose&alternative&models167.&The&
prevailing&lack&of&distinction&between&predictive&and&prognostic&factors&may&be&one&
reason168.&A&prognostic&factor&provides&information&on&the&likely&outcome&of&a&cancer&disease&
in&an&untreated&individual.&A&predictive&factor&provides&information&about&the&likely&effect&of&
a&treatment169.&&
Several&large&studies&have&recently&been&published&on&the&prognostic&significance&of&
tumor&size170,171.&Morgensztern&et&al&reported&from&the&SEER&registry,&and&identified&12&315&
patients&with&locally&advanced&stage&III&NSCLC&N2e3&disease&strictly&on&the&basis&of&TNM&
staging,&regardless&of&the&treatment.&They&found&tumor&size&to&be&an&independent&prognostic&
factor.&Ball&et&al&reported&on&868&patients&of&all&TNM&stages&included&in&The&IASLC&Staging&
Project.&The&tumor&diameters&were&known&and&the&cancers&were&subjected&to&radical&
radiotherapy&or&combined&chemoe&and&radiotherapy.&The&authors&found&that&tumor&sizes&less&
than&3&cm&were&associated&with&a&longer&survival&than&larger&tumors.&The&evidence&on&the&
prognostic&effect&for&tumors&larger&than&3&cm&was&weak.&But&the&basis&for&the&comparison&of&
all&these&studies&has&been&the&treatment&effect&on&smaller&tumors.&Accordingly,&they&do&not&
tell&us&much&about&how&treatment&on&larger&tumors&compares&to&no&treatment&or&best&
supportive&care.&&&
In&a&small&study&published&in&2008,&WernereWasik&et&al&found&that&larger&tumor&
volumes&were&associated&with&larger&risk&of&local&failure&and&smaller&tumors&were&associated&
with&improved&OS172.&Their&findings&were&not&compared&to&a&control&group.&Other&authors&
have&addressed&the&prognostic&value&of&tumor&size&and&volume&on&survival100,153,166,173.&But&
these&studies&have&concerned&patients&who&received&definitive&treatment,&and&though&large&
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tumors&were&shown&to&have&varying&degrees&of&negative&prognostic&impact,&the&treatment&
effect&was&not&specifically&addressed&in&any&of&the&studies.&It&is&important&to&stress&that&a&
poor&prognosis&does&not&preclude&an&excellent&treatment&effect.&Accordingly,&these&studies&
cannot&be&used&as&arguments&against&treating&bulky&tumors.&&
&
8.7.Paper.3.–.The.Influence.of.Age.
The&Conrad&study&was&not&designed&to&study&the&issue&CRT&and&age.&.
However,&we&find&several&arguments&for&conducting&a&study&concerning&age&and&
treatment&effect&of&CRT&among&patients&with&negative&prognostic&factors&and&noneresected&
LAeNSLCL&stage&III:&The&percentage&of&patient&≥&70&years&(42%)&was&larger&than&in&most&
similar&trials;&the&study&was&stratified&with&regards&to&age,&and&the&best&treatment&approach&
for&patients&of&this&category&has&still&not&been&determined.&&
In&several&recent&trials&of&elderly&patients&with&noneresected&LAeNSLCL&stage&III&
subjected&to&CRT,&the&reported&overall&survival&has&been&considerably&longer&than&in&our&
study151,152.&But&the&patients&have&been&given&definite&chemoradiation&with&radiation&dose&
approximately&60&Gy.&Considering&that&the&majority&of&the&elderly&patients&have&
comorbidities,&many&will&have&negative&prognostic&factors&and&only&a&minority&will&endure&
such&treatment.&&
We&found&an&increase&in&overall&survival&among&the&CRT&patients&≥&70&years&in&our&
study,&but&the&increase&was&not&significant.&However,&women&with&lung&cancer&are&known&to&
have&a&better&prognosis&than&males,&older&women&even&more&than&younger17,174.&In&our&
material&there&is&a&male&predominance&(77%&males&in&the&older&versus&55%&in&the&younger&
CRT&group).&This&may&have&influenced&the&overall&survival.&In&addition,&patients&>&75&years&in&
our&study&were&administered&25%&reduced&chemotherapy&doses.&Approximately&50%&of&the&
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older&treatment&group&(≥&70&years)&was&>&75&years&old.&Though&the&reduced&doses&may&have&
corroborated&a&favorable&hematological&profile&among&the&elderly,&the&dose&reduction&
probably&influenced&the&survival&rate&negatively.&Taking&all&these&arguments&in&to&
consideration,&with&a&1e&and&2eyear&survival&of&44&and&23&%,&respectively,&as&seen&in&our&
study,&we&have&reason&to&expect&survival&benefit&of&CRT&treatment&to&patients&≥&70&years,&
even&if&they&have&negative&prognostic&factors&and&noneresected&LAeNSLCL&stage&III.&
Wang&et&al&and&PijlseJohannesma&et&al&have&described&how&most&functional&scores&for&
HRQoL&usually&decline&over&time&and&symptoms&as&hemoptysis&and&pain&increase&later&in&the&
course&of&the&disease147,175:&Based&on&HRQoL&investigations&in&two&prospective&CRT&based&
trials&in&NSCLC&stage&III&patients,&Hallqvist&et&al&reported&a&gradual&worsening&of&dyspnea&and&
fatigue&during&the&observation&period,&regardless&of&age146.&&
In&our&study,&the&most&prominent&functional&benefit&of&CRT&for&the&elderly&was&found&
in&Global&HRQO,&which&remained&clinically&unchanged&throughout&the&treatment&and&the&
observation&periods.&CRTerelated&symptoms,&such&as&dysphagia&and&pain&in&the&treatment&
period,&were&found&to&be&transient&and&less&prominent&in&the&group&of&patients&≥&70&years.&
The&elderly&receiving&CRT&experienced&less&dyspnea&and&fatigue&than&the&elderly&noneCRT&
treated&patients.&&
&Our&study&was&only&marginally&powered&to&detect&the&main&issue&and&we&cannot&
expect&it&to&be&sufficiently&powered&to&answer&others.&The&nonesignificant&increase&in&overall&
survival&we&found&among&the&patients&receiving&CRT&is&probably&a&type&II&error.&The&benefit&in&
HRQoL&seemed&to&be&more&convincing.&
However,&if&we&relate&overall&survival&and&HRQoL&to&age,&our&conclusion&does&not&
differ&from&those&drawn&about&age&and&CRT&in&patients&with&noneresectable&locally&advanced&
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NSCLC&stage&III&by&other&authors3,152.&At&a&time&when&similar&studies&regarding&patients&in&the&
relevant&age&group&are&missing,&this&alone&must&be&considered&to&be&of&importance.&
&
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9..CONCLUSIONS.
In&a&selected&material&of&poor&prognosis&patients&with&locally&advanced&NSCLC&stage&
III,&chemoradiotherapy&(CRT)&was&superior&to&chemotherapy&alone&with&respect&to&surival&
and&HRQOL&at&the&expence&of&more&hospital&admissions&due&to&toxicity.&We&did&not&find&any&
survival&benefit&of&CRT&for&patients&with&PS&2.&&We&conclude&that&tailored&CRT&may&be&offered&
to&poor&prognosis&patients&with&locally&advanced&unresectable&NSCLC&stage&III,&as&long&as&
they&do&not&have&performance&status&2&or&worse.&&
We&explored&the&effect&of&tailored&CRT&in&poor&risk&NSCLC&patients&with&bulky&tumor&
masses.&In&a&selected&material&of&patients&with&tumors&>&7&cm&possible&to&include&in&an&
adequate&radiation&field,&we&found&a&significant&benefit&in&both&survival&and&HRQoL,&as&long&
as&the&patients&had&PS&<&2.&We&conclude&that&tumor&size&should&be&considered&a&negative&
prognostic,&but&not&a&negative&predictive&factor,&regarding&treatment.&&
We&also&explored&the&effect&of&age&≥&70&years&in&the&study&population.&We&found&
Performance&Status&and&HRQoL&to&be&preserved&even&late&in&the&observation&period&
following&tailored&CRT.&&Patients&≥&70&years&also&benefited&in&overall&survival,&but&not&
significantly.&The&study&was&not&designed&to&evaluate&the&effect&of&age&and&several&factors&
may&have&reduced&the&treatment&effect&in&the&subgroup&of&elderly&in&the&experimental&arm:&
Patients&>&75&years&received&reduced&doses&chemotherapy&and&there&was&a&male&
predominance&in&the&CRT&patients&≥&70&group.&However,&this&indicates&that&poor&prognosis&
patients&with&locally&advanced&NSCLC&stage&III&and&age&≥&70&years&deserve&further&studies&of&
tailored&CRT.&&
.
.
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10..FUTURE.PERSPECTIVES&
Today&cancer&drug&development&mostly&focuses&on&therapies&that&target&cancere
proteins,&largely&identified&from&translational&studies.&In&the&future&this&will&most&probably&
lead&to&more&individualized&treatment,&where&the&patient&will&receive&therapy&according&to&
the&mutation&status&found&in&his/her&tumor.&&Most&probably&this&will&be&a&combination&of&
targeted&therapeutic&agents&–&in&order&to&overcome&the&development&of&resistance176.&&&
These&new&therapeutic&agents&will&probably&also&influence&how&clinical&cancer&trials&
are&performed,&with&focus&shifting&to&smaller&trials,&in&which&a&greater&percentage&of&patients&
are&expected&to&benefit&from&the&therapy.&Rather&than&lumping&together&many&patients&with&
diverse&mutations,&cancer&patients&will&be&segregated&and&treated&according&to&their&
mutations14.&&
The&demographic&shift&caused&by&an&aging&population&may&mean&that&we&will&see&
more&cancer&patients&in&poor&general&condition&in&the&future.&If&this&will&be&the&case,&
chemoradiotherapy,&similar&to&what&we&have&tried&out&in&Conrad&protocol,&may&be&a&way&to&
go.&But&then&more&modern&techniques&of&radiotherapy&should&be&utilized,&and&doses&of&
chemotherapy&should&probably&not&be&reduced&in&patients&>&75&years.&&
Hopefully,&new&ways&of&screening&for&lung&cancer&and&the&public&efforts&to&stop&
smoking&will&bring&about&a&reduction&in&the&incidence&of&this&sad&disease&before&that&
happens.&
&
&
&
.
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